Back to homepage

Immunology

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Authors: Sonam Puri MD, Michael Shafique MD

This review discusses the rationale, outcomes, and challenges of combination immune checkpoint blockade in non-small-cell lung cancer (NSCLC).

More

Corrigendum: Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research

Authors: Stefania Nicola MD, Giovanni Rolla MD, Luisa Brussino MD
More

Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues

Authors: Ashutosh M Shukla MD, Aparna Wagle Shukla MD

This article reviews the expanding clinical applicability of chloroquine and related drugs includes rheumatological and cardiovascular disorders (CVD), chronic kidney disease (CKD), oncology, and a variety of nonmalarial infections.

More

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis

Authors: Martina Biggioggero MD, Andrea Becciolini MD, Chiara Crotti MD, Elena Agape MD, Ennio Giulio Favalli MD

This narrative review discusses the rationale for JAK inhibition in RA, with a special focus on the role of JAK1 selective blockade and a detailed description of available data from the results of clinical trials on upadacitinib and filgotinib.

More

Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research

Authors: Stefania Nicola MD, Giovanni Rolla MD, Luisa Brussino MD

This review focuses on the mechanisms of action, routes of administration, and efficacy of therapies for the rare genetic disorder hereditary angioedema.

More